These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27070719)

  • 1. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):681-9. PubMed ID: 27070719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral salmon calcitonin--pharmacology in osteoporosis.
    Henriksen K; Bay-Jensen AC; Christiansen C; Karsdal MA
    Expert Opin Biol Ther; 2010 Nov; 10(11):1617-29. PubMed ID: 20932224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral calcitonin.
    Maricic MJ
    Curr Osteoporos Rep; 2012 Mar; 10(1):80-5. PubMed ID: 22281725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin.
    Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
    BMC Clin Pharmacol; 2008 Sep; 8():5. PubMed ID: 18782439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats.
    Wu L; Zhang G; Lu Q; Sun Q; Wang M; Li N; Gao Z; Sun Y; Li T; Han D; Yu X; Wang L; Sun W; Zhao D; Wu Y; Lu Y; Chen X
    Drug Dev Ind Pharm; 2010 Mar; 36(3):362-70. PubMed ID: 19719396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage.
    Aguirre TAS; Aversa V; Rosa M; Guterres SS; Pohlmann AR; Coulter I; Brayden DJ
    J Control Release; 2016 Sep; 238():242-252. PubMed ID: 27480451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.
    Karsdal MA; Henriksen K; Bay-Jensen AC; Molloy B; Arnold M; John MR; Byrjalsen I; Azria M; Riis BJ; Qvist P; Christiansen C
    J Clin Pharmacol; 2011 Apr; 51(4):460-71. PubMed ID: 20660294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL; McTavish D
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats.
    Bhandari KH; Newa M; Chapman J; Doschak MR
    J Control Release; 2012 Feb; 158(1):44-52. PubMed ID: 22001608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
    J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
    Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.
    Swaminathan J; Gobbo OL; Tewes F; Healy AM; Ehrhardt C
    J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):1-11. PubMed ID: 24252061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin.
    Bhandari KH; Newa M; Uludag H; Doschak MR
    Int J Pharm; 2010 Jul; 394(1-2):26-34. PubMed ID: 20412845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin load test to assess the efficacy of salmon calcitonin.
    Stepan JJ; Zikán V
    Clin Chim Acta; 2003 Oct; 336(1-2):49-55. PubMed ID: 14500034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis.
    Liu Y; Yu P; Peng X; Huang Q; Ding M; Chen Y; Jin R; Xie J; Zhao C; Li J
    J Control Release; 2019 Jun; 304():39-50. PubMed ID: 31054990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin.
    Silverman SL
    Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.
    Perrone G; Galoppi P; Valente M; Capri O; D'Ubaldo C; Anelli G; Zichella L
    Gynecol Obstet Invest; 1992; 33(3):168-71. PubMed ID: 1612530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.